IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA

Abstract Chimeric antigen receptor (CAR)-T cell therapies are an undoubted success in childhood acute lymphoblastic leukemia; however, this has not translated clinically to any solid tumor. B7-H3 been found be highly expressed pediatric brain tumors and correlates with tumor progression poor prognosis. We utilized a novel nanobody based CAR-T which can bind antigens high affinity. hypothesize that anti-B7-H3 cells mediate more potent antitumor effects both vitro vivo compared existing antibody-based cells. High expression of was confirmed on the surface two glioblastoma lines by flow cytometry Quantibrite staining. nanobodies isolated from camel phage libraries were cloned into lentiviral constructs. manufactured transduction human T Glioblastoma co-cultured vs. control specific cytokine release via ELISA effective killing different cytotoxicity assays (impedance or luciferase based). Nanobody exhibited statistically significant higher antibody In studies currently evaluating efficacy intracerebroventricular delivery against orthotopic models utilizing multiple donor immunocompromised mice. simultaneously developing syngeneic model evaluate cross-reactive mice immunocompetent model. Careful investigation therapy appropriate is needed develop immunotherapy for clinical application.